Otsuka Pharmaceutical Co., Ltd.
otsuka.comTotal trials
143
Active
16
Phase 3
65
Total enrollment
31,754
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 15 of 15 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| OPA-15406 | — | — | — | — | 5 | ||
| OPC-34712FUM/ Brexpiprazole fumarate | — | — | — | — | 3 | ||
| EB-1020 (Centanafadine) low dose | — | — | — | — | — | 2 | |
| EB-1020 (Centanafadine) high dose | — | — | — | — | — | 2 | |
| Vehicle | — | — | — | — | — | 2 | |
| EB-1020 (Centanafadine) 164.4 mg | — | — | — | — | — | 2 | |
| EB-1020 (Centanafadine) 328.8 mg | — | — | — | — | — | 2 | |
| SEP-363856 | — | — | — | — | — | 1 | |
| OPC-415 | — | — | — | — | — | 1 | |
| ASTX727 | — | — | — | — | — | 1 | |
| Tolvaptan | — | — | — | 6 | |||
| Brexpiprazole | — | — | — | — | 5 | ||
| Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution | — | — | — | — | — | 1 | |
| Voclosporin | — | — | — | — | — | 1 | |
| Samtasu for I.V. | — | — | — | — | — | 1 |
Next readouts
- 2025-04-09
- 2025-08
- 2025-11-30
- 2026-01-31
- 2026-02
- 2026-09-30
- 2026-12
- 2027-02
- 2027-08
- 2027-08
Top conditions
- Schizophrenia11
- Major Depressive Disorder6
- Atopic Dermatitis6
- Parkinson's Disease6
- Acute Myeloid Leukemia5
- Dry Eye Syndromes5
- Cirrhosis4
- Healthy Adult Male4
Frequently asked questions about Otsuka Pharmaceutical Co., Ltd.
- How many clinical trials does Otsuka Pharmaceutical Co., Ltd. have on ClinicalTrials.gov?
- Otsuka Pharmaceutical Co., Ltd. is listed as the lead sponsor on 143 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Otsuka Pharmaceutical Co., Ltd.'s trials are in Phase 3?
- 65 of Otsuka Pharmaceutical Co., Ltd.'s trials are in Phase 3, spread across 15 active drug programs.
- What therapeutic areas does Otsuka Pharmaceutical Co., Ltd. focus on?
- Otsuka Pharmaceutical Co., Ltd.'s most-studied conditions on ClinicalTrials.gov are Schizophrenia, Major Depressive Disorder, Atopic Dermatitis, Parkinson's Disease, Acute Myeloid Leukemia.
- When are Otsuka Pharmaceutical Co., Ltd.'s next clinical trial readouts?
- Otsuka Pharmaceutical Co., Ltd. has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma”, expected around 2025-04-09.